Skip to Main Content
Table 2—

Prevalence of complications at baseline and follow-up

Men
Women
BaselineFollow-upBaselineFollow-up
n 51 48 62 57 
Retinopathy     
 Background 8 (16) 17 (36) 8 (13) 19 (33) 
 Preproliferative 5 (11) 3 (5) 
 Laser-treated 10 (21) 1 (2) 16 (28) 
Nephropathy     
 Microalbuminuria 2 (4) 1 (2) 4 (7) 
 Proteinuria 2 (4) 1 (2) 3 (5) 
 Receiving dialysis 1 (2) 1 (2) 
 Transplant 2 (4) 
 Died from renal failure 2 (4) 
Peripheral neuropathy 1 (2) 11 (19) 
Required toe amputation 1 (2) 1 (2) 
Autonomic neuropathy 4 (8) 6 (11) 
One serious complication* 16 (33) 2 (3) 7 (12) 
Two serious complications 2 (4) 6 (11) 
Three or more serious complications 1 (2) 7 (12) 
Men
Women
BaselineFollow-upBaselineFollow-up
n 51 48 62 57 
Retinopathy     
 Background 8 (16) 17 (36) 8 (13) 19 (33) 
 Preproliferative 5 (11) 3 (5) 
 Laser-treated 10 (21) 1 (2) 16 (28) 
Nephropathy     
 Microalbuminuria 2 (4) 1 (2) 4 (7) 
 Proteinuria 2 (4) 1 (2) 3 (5) 
 Receiving dialysis 1 (2) 1 (2) 
 Transplant 2 (4) 
 Died from renal failure 2 (4) 
Peripheral neuropathy 1 (2) 11 (19) 
Required toe amputation 1 (2) 1 (2) 
Autonomic neuropathy 4 (8) 6 (11) 
One serious complication* 16 (33) 2 (3) 7 (12) 
Two serious complications 2 (4) 6 (11) 
Three or more serious complications 1 (2) 7 (12) 

Data are n or n (%).

*

Defined as any one of the following: preproliferative or laser-treated retinopathy, proteinuria or more severe renal disease, peripheral neuropathy, or autonomic neuropathy.

Close Modal

or Create an Account

Close Modal
Close Modal